AleAnna (NASDAQ:ANNA – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.
Earnings and Valuation
This table compares AleAnna and TransCode Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AleAnna | $6.10 million | 37.73 | -$12.34 million | ($0.05) | -69.00 |
| TransCode Therapeutics | N/A | N/A | -$16.75 million | ($169.66) | -0.05 |
Risk & Volatility
AleAnna has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Profitability
This table compares AleAnna and TransCode Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AleAnna | N/A | -33.33% | -18.08% |
| TransCode Therapeutics | N/A | -378.30% | -186.01% |
Institutional & Insider Ownership
38.1% of AleAnna shares are owned by institutional investors. 42.9% of AleAnna shares are owned by company insiders. Comparatively, 0.0% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for AleAnna and TransCode Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AleAnna | 1 | 0 | 0 | 0 | 1.00 |
| TransCode Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
TransCode Therapeutics has a consensus target price of $280.00, suggesting a potential upside of 3,081.82%. Given TransCode Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe TransCode Therapeutics is more favorable than AleAnna.
Summary
AleAnna beats TransCode Therapeutics on 7 of the 12 factors compared between the two stocks.
About AleAnna
AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.
About TransCode Therapeutics
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Receive News & Ratings for AleAnna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AleAnna and related companies with MarketBeat.com's FREE daily email newsletter.
